Confo Therapeutics has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialization of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders.

Under the terms of the agreement, Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialization. The financial terms include an upfront payment, pre-clinical milestones and research funding to Confo Therapeutics totaling over $7 million over the first 30 month period. 

In addition, Confo Therapeutics is eligible to receive up to $96.3 million in payments for certain development, regulatory and commercial milestones, plus tiered royalties on the annual net sales of any products resulting from the collaboration.

“Securing this partnership with Roche is another significant corporate milestone for Confo Therapeutics,” said Dr. Cedric Ververken Confo chief executive officer. “The decision by a global pharmaceutical company to work with Confo Therapeutics further validates the strength of our proprietary Confo technology and the capabilities of our team. It also strengthens our resolve to vigorously pursue our own proprietary product pipeline in addition to enabling our partners to develop valuable medicines for patients.”